Remove Drug Delivery Systems Remove Drugs Remove Life Science
article thumbnail

PCI Pharma Services Invests Over $365 Million in EU, US Facilities to Drive Clinical and Commercial Supply of Advanced Drug Delivery and Drug Device Combination Products

XTalks

Highlights include expansion of biotech operations in Philadelphia, acquisition of a new pharma-device facility near Dublin, Ireland, and a new Center of Excellence for advanced drug delivery and drug-device combination product assembly in Rockford, Illinois.

article thumbnail

FDA Authorizes Pfizer COVID-19 Vaccine for Children 5 to 11 + Genentech’s Ocular Implant for Macular Degeneration – Xtalks Life Science Podcast Ep. 35

XTalks

The team also learned about the FDA approval of Genentech’s new ocular implant drug delivery system, called Susvimo, for the treatment of neovascular, or wet, age-related macular degeneration (nAMD). Genentech’s New Ocular Implant Drug Delivery System for Macular Degeneration Could Be a Game Changer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Warns of Dosing Errors with Compounded Semaglutide Injectables

XTalks

These issues primarily stem from patients and healthcare providers miscalculating or incorrectly administering the drug. Compounded semaglutide products, unlike the US Food and Drug Administration (FDA)-approved ones, can vary widely in strength and packaging, making it easy for mistakes to happen.

article thumbnail

Meeting global demand for patient independence: SHL Medical expands production in Charleston, US

Pharmaceutical Technology

SHL Medical is a world-leading solutions provider for advanced drug delivery systems with a unified purpose to further enable patient independence. Consequently, pharmaceutical and biotech companies are increasingly looking to provide devices that allow patients to self-administer drugs.

article thumbnail

Nemolizumab Approved for Adults with Prurigo Nodularis

XTalks

The US Food and Drug Administration (FDA) has approved Galderma’s monoclonal antibody Nemluvio (nemolizumab) for the treatment of adult patients with the chronic skin condition prurigo nodularis. Monoclonal antibody therapy has been found to have fewer side effects when compared to immunosuppressant drugs.

article thumbnail

Subcutaneous Biologics: The Unmet Requirement in the Pharmaceutical Space

Roots Analysis

However, several drug delivery devices that enable patients to self-administer their respective medications are now available. Biologics have emerged as a direct consequence of the rapid development that has taken place in the field of life sciences, particularly in cell and molecular biology, over the past few decades.

article thumbnail

Skin Cancer Awareness Month 2024 and Insights from Medicus Pharma

XTalks

For healthcare and life sciences industries, Skin Cancer Awareness Month helps highlight the importance of preventive measures and early detection. Drugs such as pembrolizumab (Merck’s Keytruda) and nivolumab (Bristol Myers Squibb’s Opdivo) have revolutionized the treatment options for skin cancer.